Levosalbutamol

Salbutamol (100mcg) and Ipratropium Bromide (20mcg Inhaler) combines a short-acting beta-2 agonist (SABA) with a short-acting muscarinic antagonist (SAMA) on the WHO Model List of Essential Medicines. Salbutamol relaxes bronchial smooth muscle via cyclic AMP elevation; ipratropium blocks vagal acetylcholine-mediated bronchoconstriction at muscarinic M3 receptors. This dual-pathway approach produces greater, longer-lasting bronchodilation than either agent alone without added sympathomimetic side effects. Indicated for management of bronchospasm in Chronic Obstructive Pulmonary Disease (COPD) and acute severe asthma exacerbations.

Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).

Budesonide Inhalation / Nebuliser Suspension (100mcg, 200mcg MDI; 400mcg Rotacaps; 1mg/2ml Respules) is a potent inhaled glucocorticoid on the WHO Model List of Essential Medicines. It diffuses into airway epithelial cells, binding to cytoplasmic glucocorticoid receptors to inhibit multiple pro-inflammatory transcription factors (NF-kB, AP-1), dramatically reducing recruitment of eosinophils, T-lymphocytes, and mast cells while downregulating inflammatory cytokines. Undergoes reversible intracellular esterification with fatty acids, creating a prolonged mucosal depot. Indicated for maintenance treatment of bronchial asthma, croup (laryngotracheobronchitis in infants/children), and severe COPD.

Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).

Salbutamol / Albuterol Inhalation (100mcg MDI, 200mcg Rotacaps) is the quintessential short-acting selective beta-2 adrenergic receptor agonist (SABA) on the WHO Model List of Essential Medicines. It binds to beta-2 adrenergic receptors on airway smooth muscle cells, activating adenylyl cyclase, elevating cyclic AMP, and causing rapid relaxation of bronchial smooth muscle within 3 to 5 minutes, lasting 4 to 6 hours. Indicated for immediate relief of acute bronchospasm in bronchial asthma, acute exacerbations of COPD, and prevention of exercise-induced bronchoconstriction.

Levosalbutamol (50mcg/100mcg) and Beclomethasone Dipropionate (50mcg/100mcg/200mcg Inhaler, Rotacaps) combines the active (R)-enantiomer of salbutamol with a synthetic glucocorticoid. Levosalbutamol provides rapid-acting selective beta-2 bronchodilation without the adverse tachycardia, tremor, and pro-inflammatory effects associated with the inert (S)-isomer. Beclomethasone suppresses underlying eosinophilic airway inflammation and edema. Indicated for maintenance and symptomatic treatment of mild-to-moderate bronchial asthma.

Levosalbutamol (50mcg/100mcg) and Beclomethasone Dipropionate (50mcg/100mcg/200mcg Inhaler, Rotacaps) combines the active (R)-enantiomer of salbutamol with a synthetic glucocorticoid. Levosalbutamol provides rapid-acting selective beta-2 bronchodilation without the adverse tachycardia, tremor, and pro-inflammatory effects associated with the inert (S)-isomer. Beclomethasone suppresses underlying eosinophilic airway inflammation and edema. Indicated for maintenance and symptomatic treatment of mild-to-moderate bronchial asthma.

Levosalbutamol (50mcg/100mcg) and Beclomethasone Dipropionate (50mcg/100mcg/200mcg Inhaler, Rotacaps) combines the active (R)-enantiomer of salbutamol with a synthetic glucocorticoid. Levosalbutamol provides rapid-acting selective beta-2 bronchodilation without the adverse tachycardia, tremor, and pro-inflammatory effects associated with the inert (S)-isomer. Beclomethasone suppresses underlying eosinophilic airway inflammation and edema. Indicated for maintenance and symptomatic treatment of mild-to-moderate bronchial asthma.

Budesonide Inhalation / Nebuliser Suspension (100mcg, 200mcg MDI; 400mcg Rotacaps; 1mg/2ml Respules) is a potent inhaled glucocorticoid on the WHO Model List of Essential Medicines. It diffuses into airway epithelial cells, binding to cytoplasmic glucocorticoid receptors to inhibit multiple pro-inflammatory transcription factors (NF-kB, AP-1), dramatically reducing recruitment of eosinophils, T-lymphocytes, and mast cells while downregulating inflammatory cytokines. Undergoes reversible intracellular esterification with fatty acids, creating a prolonged mucosal depot. Indicated for maintenance treatment of bronchial asthma, croup (laryngotracheobronchitis in infants/children), and severe COPD.

Salbutamol (100mcg) and Ipratropium Bromide (20mcg Inhaler) combines a short-acting beta-2 agonist (SABA) with a short-acting muscarinic antagonist (SAMA) on the WHO Model List of Essential Medicines. Salbutamol relaxes bronchial smooth muscle via cyclic AMP elevation; ipratropium blocks vagal acetylcholine-mediated bronchoconstriction at muscarinic M3 receptors. This dual-pathway approach produces greater, longer-lasting bronchodilation than either agent alone without added sympathomimetic side effects. Indicated for management of bronchospasm in Chronic Obstructive Pulmonary Disease (COPD) and acute severe asthma exacerbations.

Salbutamol / Albuterol Inhalation (100mcg MDI, 200mcg Rotacaps) is the quintessential short-acting selective beta-2 adrenergic receptor agonist (SABA) on the WHO Model List of Essential Medicines. It binds to beta-2 adrenergic receptors on airway smooth muscle cells, activating adenylyl cyclase, elevating cyclic AMP, and causing rapid relaxation of bronchial smooth muscle within 3 to 5 minutes, lasting 4 to 6 hours. Indicated for immediate relief of acute bronchospasm in bronchial asthma, acute exacerbations of COPD, and prevention of exercise-induced bronchoconstriction.

Levosalbutamol (50mcg/100mcg) and Beclomethasone Dipropionate (50mcg/100mcg/200mcg Inhaler, Rotacaps) combines the active (R)-enantiomer of salbutamol with a synthetic glucocorticoid. Levosalbutamol provides rapid-acting selective beta-2 bronchodilation without the adverse tachycardia, tremor, and pro-inflammatory effects associated with the inert (S)-isomer. Beclomethasone suppresses underlying eosinophilic airway inflammation and edema. Indicated for maintenance and symptomatic treatment of mild-to-moderate bronchial asthma.